To date, PCSK9 has been targeted using a variety of techniques, such as antisense nucleotide therapy and monoclonal antibodies aiming in uninterrupted LDLR expression and, subsequently, substantial clearance of circulating LDL (by up to 70%; Hovingh et al., 2013; Seidah et al., 2014), with reduction of ASCVD-related morbidity and mortality being the ultimate benefit in atherosclerotic and FH patients (Eisen and Giugliano, 2016; Navarese et al., 2016; Sabatine et al., 2016, 2017). This evidence concerns the gene PCSK9 and atherosclerosis.